Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Amgen, Novartis Report Positive Data for Migraine Drug

By Ryan Bushey | November 17, 2016

Amgen and Novartis are one step closer to having a contender in the migraine treatment space.

Both companies reported on Wednesday that patients diagnosed with episodic migraines taking their investigational therapy, erenumab, reported fewer debilitating headaches per month compared to the participants taking placebo, according to Endpoints News.

Investigators running this second randomized late-stage study recruited 955 patients for this test who on average experienced 8.3 migraine days each month. Patients were administered either 70mg or 140mg of the drug once a month for a six month period.  

Both dosing regimens elicited statistically significant results. The 70mg and 140mg treatment of erenumab lowered the average number of migraine days suffered by these groups down to 3.2 and 3.7 days respectively while the placebo recipients only experienced 1.8 day reduction.

These results in conjunction with previous tests evaluating the drug’s impact on chronic migraine sufferers will help these pharmaceutical companies make their case for regulatory approval.

Other companies like Allergan and Eli Lilly are developing their own migraine treatments as well.

However, Amgen and Novartis are hoping to distinguish themselves in this market because their candidate blocks the Calcitonin Gene-Related Peptide (CGRP) receptor, which is believed to play a role in causing migraines. Rival therapies only focus on the ligand.

Analysts predict this drug could have blockbuster potential pulling in $1.3 billion in sales by 2023, explained Endpoints News.


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50